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mal standard and gold standard for the assessment of weight 
management in PKU. While the former aims to underline the 
importance of nutritional status evaluation in every special-
ized clinic, the second objective is important in establishing 
an understanding of the breadth of overweight and obesity 
in PKU in Europe.  Key Messages: In PKU, the importance of 
adopting a European nutritional management strategy on 
weight management is highlighted in order to optimize 
long-term health outcomes in patients with PKU. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Historically, the main objective of phenylketonuria 
(PKU) management was to prevent profound and irre-
versible intellectual disability together with the avoidance 
of nutritional deficiencies resulting in growth impair-
ment  [1] . Traditional low phenylalanine dietary manage-
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 Abstract 
 Background: Severe intellectual disability and growth im-
pairment have been overcome by the success of early and 
continuous treatment of patients with phenylketonuria 
(PKU). However, there are some reports of obesity, particu-
larly in women, suggesting that this may be an important 
comorbidity in PKU. It is becoming evident that in addition 
to acceptable blood phenylalanine control, metabolic dieti-
cians should regard weight management as part of routine 
clinical practice.  Summary: It is important for practitioners 
to differentiate the 3 levels for overweight interpretation: 
anthropometry, body composition and frequency and se-
verity of associated metabolic comorbidities. The main ob-
jectives of this review are to suggest proposals for the mini-
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ment, and more recently with pharmacological treat-
ment, has been very successful in achieving these goals. 
However, there is concern that obesity may be a common 
comorbidity. Although in PKU there is still limited evi-
dence, some studies highlight an increased obesity risk 
particularly in females  [2–4] . It is therefore essential that 
PKU health professionals are able to conduct lifestyle 
‘risk assessments’ to identify potential obesogenic factors, 
consider trends in nutritional status by systematically 
monitoring key clinical and biochemical measures, and 
provide effective nutritional and lifestyle advice in order 
to avoid obesity. Also, it is important to standardize pro-
cedures for data collection in order to monitor trends be-
tween centres and countries. This will help clarify if over-
weight is related to the disorder, the treatment or to a 
disrupted energy balance.
 Therefore, this paper has 3 objectives: (1) to clarify def-
inition and interpretation of measurements for over-
weight and obesity; (2) to define minimal standards for 
monitoring overweight and obesity in the PKU clinic; and 
(3) to propose a ‘gold standard’ for data collection for as-
sessment of overweight, obesity and lifestyle in PKU.
 Defining and Assessing Overweight and Obesity 
 Adequate assessment depends on age and gender, and 
careful interpretation is needed particularly in childhood 
and adolescence, where the correct diagnosis of over-
weight and obesity is more challenging than in adult-
hood. Several methods exist for assessing overweight and 
obesity, all with their pros and cons.
 Body Mass Index 
 Body mass index (BMI) has been used in paediatrics 
since the 1980s  [5] and defines the widely used criteria 
for overweight and obesity in adults (BMI  ≥ 25 kg/m 2 
corresponds to overweight and BMI  ≥ 30 kg/m 2 corre-
sponds to obesity)  [6] . The preference for its use is from 
the association with body composition and disease risk 
factors, as well as being calculated by weight and height 
measurements only  [7] . In paediatrics, comparison with 
a reference population is required. Several countries 
have their own nationally representative reference popu-
lation growth charts  [7] . However, the World Health Or-
ganization (WHO) growth charts (0–5 years of age) rep-
resent a standard of physiological growth, since breast-
fed children from controlled pregnancies were included 
 [8] and they have also proposed references for children 
aged 5–19 years  [9] . Other international criteria for di-
agnosing overweight and obesity in paediatrics are avail-
able from the International Obesity Task Force (IOTF). 
Although this can be used for international descriptive 
and comparative studies, it is not designed for clinical 
use and so should not replace the national reference data 
 [10] . Nevertheless, IOTF cut-offs expressed as centiles 
permit comparisons with other international criteria like 
WHO  [11] .  Table 1 summarizes internationally available 
criteria.
 Caution is needed when interpreting results from 
studies using different criteria to classify overweight and 
obese individuals, for example, IOTF, WHO or other na-
tional data, like Centers for Disease Control and Preven-
tion (CDC)  [12] , since variable results are expected  [13] . 
In addition, more research is needed to better identify 
universal BMI cut-offs and its association with health 
outcomes later in life  [14] .
 Body Composition 
 Although BMI is the most commonly used marker 
for diagnosing overweight and obesity, it should be 
highlighted that overweight definition is based on the 
proportion of body fat to the body weight, which results 
from increased energy intake, reduced energy expendi-
Table 1.  International BMI cut-offs for classifying overweight and obesity according to different definitions
Criteria Age group Risk of 
overweight
Overweight Obesity
WHO growth charts [8] <5 years 1 SD 2 SD 3 SD
WHO growth charts [9] 5–19 years – 1 SD 2 SD
CDC growth charts [12] 2–20 years – 1 SD 2 SD
IOTF [11] 2–18 years – Cut-off corresponding 
to a BMI of 25 kg/m2 
at 18 years
Cut-off corresponding 
to a BMI of 30 kg/m2 
at 18 years
WHO adults [6] Adults – 25≤ BMI <30 kg/m2 BMI ≥30 kg/m2
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ture or both  [15] . According to WHO, the ‘real or clinic’ 
overweight is perceived when the adiposity level is suf-
ficiently high to increase morbidity and mortality  [15] . 
Although considered a good screening tool, BMI may 
not always identify the overfat individuals (increased fat 
mass percentage), since a stunted linear growth may be 
responsible for the increased BMI  [16] . Even in adults, 
a rigorous assessment and careful interpretation be-
tween BMI and health outcome are needed, since these 
relationships are not always clear  [17] . Considering the 
wide range of methods available for measuring body 
composition, it is important to refer that these start with 
the predictive techniques (skinfold thicknesses and bio-
electrical impedance analysis), then reference methods 
like dual energy X-ray absorptiometry, isotope dilution 
and air displacement plethysmography, finalizing with 
the gold standard methods (4-component model for 
quantifying fat, water, mineral and protein and magnet-
ic resonance imaging for quantifying fat distribution) 
 [18] .
 Metabolic Comorbidities 
 The relationship between BMI and disease is mediat-
ed by a metabolically abnormal phenotype mainly char-
acterized by dyslipidemia, hypertension, insulin resis-
tance and inflammation, all coexisting with increased ab-
dominal obesity  [19, 20] . So, in addition to ‘overweight’, 
it is increasingly important to define overfat individuals 
and particularly those at increased risk of metabolic dis-
turbances. Further, considering that visceral adipose tis-
sue assumes great relevance in terms of the inflamma-
tory impact of the adipose tissue between metabolic syn-
drome and allied comorbidities  [21, 22] , understanding 
the main location of body fat deserves clinical attention. 
Further study is particularly required to investigate if 
overweight in PKU is associated with the same abnormal 
metabolic patterns usually seen in the general population 
 [23] .
 Assessment of Overweight, Obesity and Lifestyle in 
Patients with PKU 
 Published results on overweight and obesity in 
PKU patients are contradictory; most of them are only 
representative of single PKU centres and they mainly 
include children and adolescents  [23] . Not all studies 
demonstrate overweight in patients with PKU  [2, 4, 
 24–27] , but a developing trend suggests that over-
weight in PKU is following the general population  [2, 
4, 26, 27] . However, this outcome should not be com-
mended, as PKU health care professionals should also 
focus on general health and prevention of overweight is 
essential.
 Minimal Standards for Monitoring Overweight and 
Obesity in the PKU Clinic 
 Minimal standards for monitoring overweight and 
obesity are proposed in PKU ( table 2 ).
 Delaying diagnosis and treatment of overweight will 
reduce the chances of a successful intervention. The con-
cept of diet for life adopted in PKU management  [31] 
Table 2.  Minimal standards for monitoring overweight and obesity in the PKU clinic
Measure Justification Practicalities/check-points
Dietary intake and life-style
Diet Diet will modulate the risk 
of developing overweight and  obesity
Total protein, amino acid and natural protein intakes
Total energy intakes




Life-style will modulate the risk 
of developing overweight and  obesity
Daily main occupation: student, employed or no occupation
Practice of structured exercise: yes or no
Anthropometry
BMI Good epidemiological marker Weight and height should be measured with the same equipment and at 




Will give a picture about the  severity 
of overweight
Fasting blood glucose and blood lipids: total cholesterol, HDL, LDL, 
triglycerides
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should guide health care professionals into caring for all 
aspects of health and not solely focused on phenylalanine 
levels.
 Proposed ‘Gold Standard’ Assessment for Data 
Collection in PKU 
 In PKU, in order to understand the European preva-
lence of overweight and obesity, it is important to assess 
and collect data in a standardized manner.  Table 3 de-
scribes a proposed ‘gold standard assessment’ tool. From 
the beginning, it is important to differentiate between 
cross-sectional and longitudinal data. Cross-sectional 
data will give an indication of the population under im-
mediate follow-up; longitudinal data will demonstrate 
the evolution of overweight and obesity and a careful 
interpretation of data will allow the identification of 
critical periods, helping to clarify if specific PKU treat-
ment strategies have an obesogenic effect. Some studies 
have already identified adolescence, especially in fe-
males  [2, 4, 28] , and early infancy  [29] , as critical peri-
ods, thereby requiring particular attention. Preventing 
an early BMI rebound  [29] and an understanding of 
Table 3.  Proposed ‘gold standard’ assessment for data collection in PKU
Measure Justification Practicalities/check-points
Dietary intake and life-style
Diet Diet will modulate the risk of 
developing overweight and obesity
Total protein, amino acid and natural protein intakes
Total energy intakes and % of calories from fat and carbohydrate
Carbohydrate intakes, mainly amounts of mono and disaccharide ingestion
BH4-treated patients analysed separately
BH4-treated patients diet patterns detailed
Low protein food intake: types, categories and % of the total daily energy intake
Social and 
life-style
Life-style will modulate the risk of 
developing overweight and obesity
Daily main occupation: student, employed or no occupation
Frequency, duration and intensity of physical activity and exercise activities
Eating patterns behaviour; frequency of snacks
Patient/caregiver knowledge about healthy foods in PKU
Anthropometry and body composition
BMI Good epidemiological marker Need to use standard methods and calibrated equipment’s
Weight and height should be measured with the same equipment and at the 
same moment of the day (morning or afternoon)
Waist 
circumference
Good association with 
abdominal adiposity
Need to use standard technique
Need to have trained heath care professionals
Body 
composition
To differentiate overweight from 
overfat and to help nutritional status 
interpretation
To select an available method in each clinic
To follow standardized procedure in every measurements in order to obtain at 




Insulin resistance is on the basis of 
metabolic syndrome
To measure fasting blood glucose
Add A1C haemoglobin and insulin, especially when insulin resistance is 
suspected to occur (presence of visceral obesity)
Lipid 
metabolism
Dislipidemia is an important feature 
of metabolic syndrome being linked 
with insulin resistance
To measure blood total cholesterol, HDL, LDL, triglycerides
Need to control the fasting time period in order to have reliable markers
Apolipoproteins measurement would be recommended
Inflammation Inflammatory markers are 
associated with abdominal obesity
To measure c-reactive protein, especially high-sensitivity c-reactive protein
When possible, cytokines could be monitored, especially in the presence of 
visceral obesity
Other clinical data
Blood pressure It is a metabolic syndrome 
component well associated with 
the global cardiovascular risk
Use standard techniques and procedures
The presence of the ‘white coat effect’ should be recognized
Careful interpretation is needed in paediatrics
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feeding and lifestyle behaviour during adolescence 
should be beneficial  [30] (see  table 4 for patient and fam-
ily data collection).
 Importance of Data Collection in Clinical Setting 
 Adopting standard procedures to monitor dietary in-
take, weight gain, body composition and clinical bio-
chemistry within the clinical setting not only enables sys-
tematic monitoring of nutritional status. It will also en-
able the application of early preventative action to avoid 
the development of overweight and obesity. This should 
help in the provision of appropriate dietary counselling 
on the use of special low-protein foods; type of phenylal-
anine-free  L -amino acid supplement; choice of natural 
protein sources particularly in sapropterin responsive pa-
tients who may have a higher natural protein tolerance; 
and also any requirement for additional exercise pro-
grammes.
 Conclusion 
 In PKU, nutritional status, particularly being over-
weight, deserves our attention as it influences long-term 
health status. Until now, the limited evidence within the 
field of overweight in PKU does not clarify if this is a seri-
ous issue in this special group of individuals. There is an 
urgent need to have a systematic and standardized over-
weight-related data collection in European representative 
cohorts of PKU patients, so that different treatment inter-
ventions and approaches can be compared.
 Disclosure Statement 
 H.G.O., K.A., K.D., A.M.L., M.R., E.D. and J.C.R. are members 
of the European Nutrition Expert Panel, which is supported by 
Merck Serono.
 C.H. was a member of the European Nutrition Expert Panel, 
which is supported by Merck Serono.
 A.M. has received research funding and honoraria from Nutri-
cia, Vitaflo International and Merck Serono, Member of European 
Nutrition Expert Panel (Merck Serono international), Member of 
Sapropterin Advisory Board (Merck Serono international), Mem-
ber of the Advisory Board Element (Danone-Nutricia) and Arla 
Advisory Board.
 M.R. is a Danone Research and Development consultant, 
Member of the Advisory Board Element (Danone-Nutricia), re-
ceived financial research support of Nutricia Netherlands and re-
ceived honoraria for lecturing and guideline development (Nutri-
cia, SSIF-Excemed).
 A.B.-Q. is a member of the European Nutrition Expert Panel 
(Merck Serono) and member of Sapropterin Advisory Board 
(Merck Serono).
 Sources of Funding 
 No specific funding for each author or for the manuscript prep-
aration was needed. 
Table 4.  Patients’, families’ and other longitudinal data to be collected in patients with PKU
Measure Justification Practicalities/check-points
Patient-related data
Disorder Disorder severity may affect metabolism, dietary 
restrictions, adherence and metabolic control
Classification in terms of HPA, mild PKU or classical PKU




Early health and nutrition are important 




Amount of total protein intake in the first 1–2 years of life
Degree of prematurity
Weight gain pattern in the first years of life
Age at BMI rebound
Age at menarche
Other disorders/comorbidities and/or exposure to chronic 




Family overweight is positively associated with 
patients tendency
Identify the presence of overweight or obesity in both parents
Are there other siblings with overweight or obesity?
Examine dietary pattern of the family
Document parental BMI and waist circumference
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